Vistagen

12/17/2025

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder: https://bit.ly/3XVPOw1

12/02/2025

Social anxiety disorder is a profound fear of being watched, judged, or embarrassed, even in everyday situations like school or work. Often beginning in adolescence, it can last for years and show up in different ways depending on life stage, job, or external pressures. Hear our CEO, Shawn Singh, discuss the impacts of social anxiety disorder on the
Inside Biotech podcast.

12/01/2025

Vistagen is pleased to announce the appointment of Nick Tressler as Chief Financial Officer, effective today, December 1, 2025. Mr. Tressler brings over 20 years of financial leadership experience in the life sciences industry guiding companies through pivotal growth and transformation. Learn more here: https://bit.ly/4oqxply

11/26/2025

Exploratory data presented at The Menopause Society 2025 Annual Meeting demonstrate PH80’s potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms (hot flashes) due to menopause. Research supports the product candidate’s non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkers. Read more: https://bit.ly/4inpYdG

11/13/2025

Vistagen today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate update. Read more: https://bit.ly/4p43qRe

11/13/2025

Vistagen will host a conference call and webcast today at 2:00 p.m. PT (5:00 p.m. ET) to report results for its fiscal year 2026 second quarter ended September 30, 2025, and provide a corporate update. Join here: https://bit.ly/3WPTcrK

11/12/2025

This World Mental Health Day, CEO Shawn Singh sat down with Michael Spector at the Nasdaq MarketSite to discuss our vision to pioneer next-generation mental health treatments. Watch here:

11/10/2025

Vistagen will host a conference call and webcast on Thursday, November 13, 2025, at 2:00 p.m. PT (5:00 p.m. ET) to report results for its fiscal year 2026 second quarter ended September 30, 2025, and provide a corporate update. For details: https://bit.ly/4oyoorN

11/05/2025

Vistagen President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation at the Stifel Healthcare Conference on Wednesday, November 12 from 3:20-3:50 p.m. ET. The Company will also host one-on-one meetings during the conference. For information on the live webcast, visit: https://bit.ly/494wPpU

11/03/2025

Vistagen today announced that the last patient has completed the randomized, double-blind, placebo-controlled portion of the PALISADE-3 Phase 3 clinical trial evaluating fasedienol for the acute treatment of social anxiety disorder. The open label extension of the study is currently ongoing, and topline results for the trial are expected by year end. Read more: https://bit.ly/47SGQFj

10/31/2025

CEO Shawn Singh got the chance to sit down with Colin Miller on Fractals: Life Science Conversations to discuss everything from his journey in the life sciences industry to Vistagen’s clinical stage pipeline. Thanks for having us and for spotlighting the exciting work Vistagen is doing!

Insightful, informative, and warmly good-humored, Fractals features life sciences leaders sharing wisdom, career highs and lows, and compelling stories from the intersections of clinical development, health care, and technology. Presented by The Bracken Group.

10/29/2025

We welcome Mr. Paul Edick to Vistagen's Board of Directors. Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy. Following the appointment of Mr. Edick, Vistagen’s Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. Read more about his distinguished record of leadership: https://bit.ly/435nvhA